Table 2.
An overview of the ongoing clinical trials of cardio-protective agents with patients receiving anticancer drugs.
| Population | Intervention | Pharmacological Class | Phase | Primary Outcome | NCT Identifier |
|---|---|---|---|---|---|
| Patients with ES, OS, and AML scheduled for chemotherapy | Captopril | ACE-I | 3 | Effect of ACE-Is in preventing chemotherapy-related cardiotoxicity | NCT03389724 |
| Patients scheduled for anthracycline | Ivabradine | Selective inhibitor of If | NA | Reduction in the global longitudinal strain of at least 10% | NCT03650205 |
| Early breast cancer patients eligible for anthracycline +/- trastuzumab | Bisoprolol; ramipril | bB and ACE-I | 3 | Maximum change in the LVEF | NCT02236806 (SAFE) |
| Breast cancer patients eligible for anthracycline treatment | Sulforaphane | Nutritional supplement | 1/2 | Change in cardiac function after doxorubicin | NCT03934905 |
| NHL patients scheduled for (R)CHOP type treatments | Atorvastatin | Lipid- lowering statin | 2 | LVEF preservation at 12 months | NCT02943590 (STOP-CA) |
| Adolescent patients after a bone marrow transplantation for hematological malignancies | Sacubitril, valsartan | Neprilysin inhibitor and ACE-I | NA | Change in the left ventricular function | NCT04092309 |
| Breast cancer patients treated with doxorubicin | Alfacalcidol | Vitamin D | 2 | Change in the plasma levels of troponin-T | NCT04166253 |
| Breast cancer patients scheduled for anthracycline | Alpha-lipoic acid | Dietary supplement | NA | Serum brain natriuretic peptide, neurotensin, and TNF-α level plasma assessment | NCT03908528 |
| Early breast cancer patients eligible for anthracycline | Xinmailong | Bioactive fraction extracted from Periplaneta Americana (American cockroach) | 2 | Rate of no cardiac events during chemotherapy | NCT03785704 |
| Early breast cancer patients eligible for anthracycline | Atorvastatin | Lipid- lowering statin | 2 | LVEF preservation at 24 months |
NCT01988571 (PREVENT) |
| Chemotherapy patients at risk of cardiotoxicity | ACE-I and bB | ACE-I and bB | NA | New LV dysfunction, as defined based on a 3D echo | ACTRN12614000341628 (SUCCOUR) |
Source: NCTtrial.gov (last access: 31 August 2020). ACE-I: angiotensin-converting enzyme inhibitor; AML: acute myeloblastic leukemia; bB: beta blocker; ES: Ewing sarcoma; If: funny channel current; LV: left ventricle; LVEF: left ventricular ejection fraction; NA: not applicable; NCT: National clinical trial; OS: osteosarcoma; (R)CHOP: chemotherapy protocol with (Rituximab) cyclophosphamide, doxorubicin, vincristine, and prednisolone.